Trial · NCT01856868
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in Muscle Tissue PGC1alpha (AU) at 8 Weeks | Baseline and 8 Weeks | Western blot measurement of the transcriptional coactivator gene PGC1alpha involved in mitochondrial biogenesis will be assessed using relative band intensities of the pre-treatment (Baseline) and post-treatment (8 Weeks) specimens with digitally quantified using ImageJ software. |
| Primary | Mean Change From Baseline in Muscle Tissue AMPK at 8 Weeks | 8 weeks | Western blot measurement of AMPK will be assessed using relative band intensities of the pre-treatment and post-treatment specimens with digitally quantified using ImageJ software). |
| Primary | Mean Change From Baseline in Muscle Tissue LKB1 at 8 Weeks | 8 weeks | Western blot measurement of LKB1 will be assessed using relative band intensities of the pre-treatment and post-treatment specimens with digitally quantified using ImageJ software) . |
| Primary | Mean Change From Baseline in Cristae-associated Mitofillin Levels at 8 Weeks | 8 weeks | Western blot measurement of Mitofillin will be assessed using relative band intensities of the pre-treatment and post-treatment specimens with digitally quantified using ImageJ software. |
| Primary | Mean Change From Baseline in Muscle Tissue Follistatin at 8 Weeks | 8 weeks | Regulators of muscle growth and regeneration including follistatin will be assessed by Western using relative band intensities of the pre-treatment and post-treatment specimens with digitally quantified using ImageJ software). |
| Primary | Mean Change From Baseline in Muscle Tissue Myostatin at 8 Weeks | 8 weeks | Regulators of muscle growth and regeneration including myostatin will be assessed by Western using relative band intensities of the pre-treatment and post-treatment specimens with digitally quantified using ImageJ software). |
| Primary | Mean Change From Baseline in Muscle Tissue Myogenin at 8 Weeks | 8 weeks | Modulators of skeletal muscle regeneration by Western will include myogenin will be assessed using relative band intensities of the pre-treatment and post-treatment specimens with digitally quantified using ImageJ software). |
| Primary | Mean Change From Baseline in Muscle Tissue Myf5 at 8 Weeks | 8 weeks | Modulators of skeletal muscle regeneration My5 will be assessed by Western using relative band intensities of the pre-treatment and post-treatment specimens with digitally quantified using ImageJ software). |
| Primary | Mean Change From Baseline in Muscle Tissue MyoD at 8 Weeks | 8 weeks | Modulators of skeletal muscle regeneration MyoD will be assessed by Western using relative band intensities of the pre-treatment and post-treatment specimens with digitally quantified using ImageJ software). |
| Primary | Mean Change From Baseline in Muscle Tissue MEF2a at 8 Weeks | 8 weeks | Modulators of skeletal muscle regeneration MEF2a will be assessed by Western using relative band intensities of the pre-treatment and post-treatment specimens with digitally quantified using ImageJ software). |
| Primary | Mean Change From Baseline in Muscle Tissue Dysferlin at 8 Weeks | 8 weeks | Structure associated indicators including dysferlin will be assessed by Western using relative band intensities of the pre-treatment and post-treatment specimens with digitally quantified using ImageJ software). |
| Primary | Mean Change From Baseline in Muscle Tissue Utrophin at 8 Weeks | 8 weeks | Structure associated indicators including utrophin will be assessed by Western using relative band intensities of the pre-treatment and post-treatment specimens with digitally quantified using ImageJ software). |
| Secondary | -(-)Epicatechin Pharmacokinetics | 8 Weeks | Pharmacokinetics sequentially after dosing will be measured. |
| Secondary | Participants With Abnormal Treatment-Related Laboratory Assessments | 8 weeks | Standard safety monitoring of plasma hematologic, hepatologic, renal and metabolic parameters will be assessed. Abnormal will be defined as values outside of typical range for patients with Becker Muscular Dystrophy. |
| Secondary | Change From Baseline in Knee Extension at 8 Weeks | Baseline and 8 Weeks | Knee extension will be assessed using an isokinetic dynamometer. |
| Secondary | Change From Baseline in 6-Minute Walk Distance at 8 Weeks | Baseline and 8 Weeks | Muscle function will be assessed by measuring the 6-minute walk distance |
| Secondary | Change From Baseline in Stand From Supine at 8 Weeks | Baseline and 8 Weeks | Muscle burst function will be assessed by time function tests. |
| Secondary | Change From Baseline in Elbow Flexion at 8 Weeks | Baseline and 8 Weeks | Elbow flexion will be assessed using an isokinetic dynamometer. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01856868/registered